Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Cristofanilli

Showing results (361-370 of 442) with videos related to

Pageof 45
Sort By:
The Lancet. Oncology|September 9, 2019
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysisMario Giuliano, Francesco Schettini, Carla Rognoni, et al.
Molecular Cancer Therapeutics|September 14, 2012
Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancerAntonio Giordano, Hui Gao, Simone Anfossi, et al.
Annals of Surgery|October 29, 2024
Mutant KRAS in Circulating Tumor DNA as a Biomarker in Localized Pancreatic Cancer in Patients Treated with Neoadjuvant ChemotherapyDominic J Vitello, Dhavan Shah, Amy Wells, et al.
Critical Reviews in Oncology/Hematology|August 19, 2024
Unveiling the impact of circulating tumor cells: Two decades of discovery and clinical advancements in solid tumorsCarolina Reduzzi, Eleonora Nicolo', Surbhi Singhal, et al.
Molecular Oncology|December 20, 2019
NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancersFrançois Bertucci, Charlotte Rypens, Pascal Finetti, et al.
Breast Cancer Research : BCR|October 2, 2023
Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysisLorenzo Gerratana, Andrew A Davis, Marko Velimirovic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2018
Combined Blockade of Activating <i>ERBB2</i> Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast CancerSarah Croessmann, Luigi Formisano, Lisa N Kinch, et al.
Biorxiv : the Preprint Server for Biology|April 16, 2025
Rare Subset of T Cells Form Heterotypic Clusters with Circulating Tumor Cells to Foster Cancer MetastasisDavid Scholten, Lamiaa El-Shennawy, Yuzhi Jia, et al.
Plos One|July 25, 2015
Inflammation Mediated Metastasis: Immune Induced Epithelial-To-Mesenchymal Transition in Inflammatory Breast Cancer CellsEvan N Cohen, Hui Gao, Simone Anfossi, et al.
European Journal of Cancer (Oxford, England : 1990)|June 23, 2024
Effect of age on safety and efficacy of novel cancer drugs investigated in early-phase clinical trialsEleonora Nicolò, Sara Gandini, Federica Giugliano, et al.
Pageof 45

Showing results (361-370 of 442) with videos related to

Sort By:
Pageof 45
The Lancet. Oncology|September 9, 2019
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysisMario Giuliano, Francesco Schettini, Carla Rognoni, et al.
Molecular Cancer Therapeutics|September 14, 2012
Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancerAntonio Giordano, Hui Gao, Simone Anfossi, et al.
Annals of Surgery|October 29, 2024
Mutant KRAS in Circulating Tumor DNA as a Biomarker in Localized Pancreatic Cancer in Patients Treated with Neoadjuvant ChemotherapyDominic J Vitello, Dhavan Shah, Amy Wells, et al.
Critical Reviews in Oncology/Hematology|August 19, 2024
Unveiling the impact of circulating tumor cells: Two decades of discovery and clinical advancements in solid tumorsCarolina Reduzzi, Eleonora Nicolo', Surbhi Singhal, et al.
Molecular Oncology|December 20, 2019
NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancersFrançois Bertucci, Charlotte Rypens, Pascal Finetti, et al.
Breast Cancer Research : BCR|October 2, 2023
Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysisLorenzo Gerratana, Andrew A Davis, Marko Velimirovic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2018
Combined Blockade of Activating <i>ERBB2</i> Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast CancerSarah Croessmann, Luigi Formisano, Lisa N Kinch, et al.
Biorxiv : the Preprint Server for Biology|April 16, 2025
Rare Subset of T Cells Form Heterotypic Clusters with Circulating Tumor Cells to Foster Cancer MetastasisDavid Scholten, Lamiaa El-Shennawy, Yuzhi Jia, et al.
Plos One|July 25, 2015
Inflammation Mediated Metastasis: Immune Induced Epithelial-To-Mesenchymal Transition in Inflammatory Breast Cancer CellsEvan N Cohen, Hui Gao, Simone Anfossi, et al.
European Journal of Cancer (Oxford, England : 1990)|June 23, 2024
Effect of age on safety and efficacy of novel cancer drugs investigated in early-phase clinical trialsEleonora Nicolò, Sara Gandini, Federica Giugliano, et al.
Pageof 45